192 related articles for article (PubMed ID: 30870043)
21. Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy.
Sundara YT; Kostine M; Cleven AH; Bovée JV; Schilham MW; Cleton-Jansen AM
Cancer Immunol Immunother; 2017 Jan; 66(1):119-128. PubMed ID: 27853827
[TBL] [Abstract][Full Text] [Related]
22. Progress and opportunities for immune therapeutics in osteosarcoma.
Lettieri CK; Appel N; Labban N; Lussier DM; Blattman JN; Hingorani P
Immunotherapy; 2016 Oct; 8(10):1233-44. PubMed ID: 27605071
[TBL] [Abstract][Full Text] [Related]
23. A coreceptor interaction between the CD28 and TNF receptor family members B and T lymphocyte attenuator and herpesvirus entry mediator.
Gonzalez LC; Loyet KM; Calemine-Fenaux J; Chauhan V; Wranik B; Ouyang W; Eaton DL
Proc Natl Acad Sci U S A; 2005 Jan; 102(4):1116-21. PubMed ID: 15647361
[TBL] [Abstract][Full Text] [Related]
24. The Immunosuppressive Niche of Soft-Tissue Sarcomas is Sustained by Tumor-Associated Macrophages and Characterized by Intratumoral Tertiary Lymphoid Structures.
Chen L; Oke T; Siegel N; Cojocaru G; Tam AJ; Blosser RL; Swailes J; Ligon JA; Lebid A; Morris C; Levin A; Rhee DS; Johnston FM; Greer JB; Meyer CF; Ladle BH; Thompson ED; Montgomery EA; Choi W; McConkey DJ; Anders RA; Pardoll DM; Llosa NJ
Clin Cancer Res; 2020 Aug; 26(15):4018-4030. PubMed ID: 32332015
[TBL] [Abstract][Full Text] [Related]
25. Association between Tim‑3 and Gal‑9 expression and gastric cancer prognosis.
Wang Y; Zhao E; Zhang Z; Zhao G; Cao H
Oncol Rep; 2018 Oct; 40(4):2115-2126. PubMed ID: 30106451
[TBL] [Abstract][Full Text] [Related]
26. Pro-inflammatory chemokine-chemokine receptor interactions within the Ewing sarcoma microenvironment determine CD8(+) T-lymphocyte infiltration and affect tumour progression.
Berghuis D; Santos SJ; Baelde HJ; Taminiau AH; Egeler RM; Schilham MW; Hogendoorn PC; Lankester AC
J Pathol; 2011 Feb; 223(3):347-57. PubMed ID: 21171080
[TBL] [Abstract][Full Text] [Related]
27. Design of short peptides to block BTLA/HVEM interactions for promoting anticancer T-cell responses.
Spodzieja M; Lach S; Iwaszkiewicz J; Cesson V; Kalejta K; Olive D; Michielin O; Speiser DE; Zoete V; Derré L; Rodziewicz-Motowidło S
PLoS One; 2017; 12(6):e0179201. PubMed ID: 28594868
[TBL] [Abstract][Full Text] [Related]
28. A Review of T-Cell Related Therapy for Osteosarcoma.
Yoshida K; Okamoto M; Aoki K; Takahashi J; Saito N
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32664248
[TBL] [Abstract][Full Text] [Related]
29. The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activation.
Cai G; Freeman GJ
Immunol Rev; 2009 May; 229(1):244-58. PubMed ID: 19426226
[TBL] [Abstract][Full Text] [Related]
30. Immune checkpoint molecule herpes virus entry mediator is overexpressed and associated with poor prognosis in human glioblastoma.
Han MZ; Wang S; Zhao WB; Ni SL; Yang N; Kong Y; Huang B; Chen AJ; Li XG; Wang J; Wang DH
EBioMedicine; 2019 May; 43():159-170. PubMed ID: 30987862
[TBL] [Abstract][Full Text] [Related]
31. Expression of programmed death ligand 1 in drug-resistant osteosarcoma: An exploratory study.
Skertich NJ; Chu F; Tarhoni IA; Szajek S; Borgia JA; Madonna MB
Surg Open Sci; 2021 Oct; 6():10-14. PubMed ID: 34386763
[TBL] [Abstract][Full Text] [Related]
32. Immune Checkpoint Molecules on Tumor-Infiltrating Lymphocytes and Their Association with Tertiary Lymphoid Structures in Human Breast Cancer.
Solinas C; Garaud S; De Silva P; Boisson A; Van den Eynden G; de Wind A; Risso P; Rodrigues Vitória J; Richard F; Migliori E; Noël G; Duvillier H; Craciun L; Veys I; Awada A; Detours V; Larsimont D; Piccart-Gebhart M; Willard-Gallo K
Front Immunol; 2017; 8():1412. PubMed ID: 29163490
[TBL] [Abstract][Full Text] [Related]
33. Cancer-germline gene expression in pediatric solid tumors using quantitative real-time PCR.
Jacobs JF; Brasseur F; Hulsbergen-van de Kaa CA; van de Rakt MW; Figdor CG; Adema GJ; Hoogerbrugge PM; Coulie PG; de Vries IJ
Int J Cancer; 2007 Jan; 120(1):67-74. PubMed ID: 17019710
[TBL] [Abstract][Full Text] [Related]
34. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
35. B and T lymphocyte attenuator mediates inhibition of tumor-reactive CD8+ T cells in patients after allogeneic stem cell transplantation.
Hobo W; Norde WJ; Schaap N; Fredrix H; Maas F; Schellens K; Falkenburg JH; Korman AJ; Olive D; van der Voort R; Dolstra H
J Immunol; 2012 Jul; 189(1):39-49. PubMed ID: 22634623
[TBL] [Abstract][Full Text] [Related]
36. Expression of Immune Checkpoint Regulators IDO, VISTA, LAG3, and TIM3 in Resected Pancreatic Ductal Adenocarcinoma.
Popp FC; Capino I; Bartels J; Damanakis A; Li J; Datta RR; Löser H; Zhao Y; Quaas A; Lohneis P; Bruns CJ; On Behalf Of The Pancalyze Study Group
Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34072549
[TBL] [Abstract][Full Text] [Related]
37. BTLA-HVEM Couple in Health and Diseases: Insights for Immunotherapy in Lung Cancer.
Demerlé C; Gorvel L; Olive D
Front Oncol; 2021; 11():682007. PubMed ID: 34532285
[TBL] [Abstract][Full Text] [Related]
38. Ki67 and lymphocytes in the pretherapeutic core biopsy of primary invasive breast cancer: positive markers of therapy response prediction and superior survival.
Schlotter CM; Tietze L; Vogt U; Heinsen CV; Hahn A
Horm Mol Biol Clin Investig; 2017 Sep; 32(2):. PubMed ID: 28937963
[TBL] [Abstract][Full Text] [Related]
39. Auto T cells expressing chimeric antigen receptor derived from auto antibody might be a new treatment for osteosarcoma.
Weibo P; Zhaoming Y
Med Hypotheses; 2012 May; 78(5):616-8. PubMed ID: 22330890
[TBL] [Abstract][Full Text] [Related]
40. HVEM has a broader expression than PD-L1 and constitutes a negative prognostic marker and potential treatment target for melanoma.
Malissen N; Macagno N; Granjeaud S; Granier C; Moutardier V; Gaudy-Marqueste C; Habel N; Mandavit M; Guillot B; Pasero C; Tartour E; Ballotti R; Grob JJ; Olive D
Oncoimmunology; 2019; 8(12):e1665976. PubMed ID: 31741766
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]